Proteins for life

We're Here To Solve Your Biggest Protein Challenges

ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.

The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.

Latest press release

ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important…

Read more